Single tertiary cancer center experience on the management of pT3b prostate cancer after robotic-assisted laparoscopic prostatectomy.
Prostate cancer
Radiotherapy
Robotic prostatectomy
Seminal vesicle
T3b
Journal
Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
30
10
2021
accepted:
16
12
2021
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
ppublish
Résumé
Pathological involvement of the seminal vesicle poses a treatment dilemma following robotic prostatectomy. Margin status plays an important role in deciding further management. A wide range of treatment options are available, including active monitoring, adjuvant radiotherapy, salvage radiotherapy, and occasionally androgen deprivation therapy. Patients undergoing postoperative radiotherapy tend to have higher risk of urinary and bowel morbidities. The recent RADICALS-RT concluded that adjuvant radiotherapy did not have any benefit compared with salvage radiotherapy. We aim to audit the incidence, margin status, and management of T3b cancer cases at our center. A retrospective analysis was conducted of all patients diagnosed with pathological T3b (pT3b) prostate cancer following robotic-assisted laparoscopic prostatectomy from January 2012 to July 2020. Preoperative parameters analyzed included prostate-specific antigen (PSA), T stage, and age. A chi-square test and 2-tailed A total of 83 (5%) of 1665 patients who underwent robotic prostatectomy were diagnosed with pT3b prostate cancer between January 2012 and July 2020. Among these, 36 patients (44%) did not receive any radiotherapy during follow-up, compared with 26 patients (31%) who received adjuvant radiotherapy and 21 (25%) who received salvage radiotherapy. The median age of our cohort was 64 (SD, 6.4) years. Mean PSA at presentation was 12.7 μg/L. Positive margins were seen in 36 patients (43%); however, there was no statistically significant difference between treatment groups ( Our audit corroborates with the recently concluded RADICALS-RT study, although we had fewer patients with positive margins. Radiotherapy can be avoided in patients with T3b prostate cancer, even if margin is positive, until there is definitive evidence of PSA recurrence. In keeping with the conclusion of RADICALS-RT, salvage radiotherapy may be preferable to adjuvant radiotherapy.
Sections du résumé
Background
UNASSIGNED
Pathological involvement of the seminal vesicle poses a treatment dilemma following robotic prostatectomy. Margin status plays an important role in deciding further management. A wide range of treatment options are available, including active monitoring, adjuvant radiotherapy, salvage radiotherapy, and occasionally androgen deprivation therapy. Patients undergoing postoperative radiotherapy tend to have higher risk of urinary and bowel morbidities. The recent RADICALS-RT concluded that adjuvant radiotherapy did not have any benefit compared with salvage radiotherapy. We aim to audit the incidence, margin status, and management of T3b cancer cases at our center.
Materials and methods
UNASSIGNED
A retrospective analysis was conducted of all patients diagnosed with pathological T3b (pT3b) prostate cancer following robotic-assisted laparoscopic prostatectomy from January 2012 to July 2020. Preoperative parameters analyzed included prostate-specific antigen (PSA), T stage, and age. A chi-square test and 2-tailed
Results
UNASSIGNED
A total of 83 (5%) of 1665 patients who underwent robotic prostatectomy were diagnosed with pT3b prostate cancer between January 2012 and July 2020. Among these, 36 patients (44%) did not receive any radiotherapy during follow-up, compared with 26 patients (31%) who received adjuvant radiotherapy and 21 (25%) who received salvage radiotherapy. The median age of our cohort was 64 (SD, 6.4) years. Mean PSA at presentation was 12.7 μg/L. Positive margins were seen in 36 patients (43%); however, there was no statistically significant difference between treatment groups (
Conclusions
UNASSIGNED
Our audit corroborates with the recently concluded RADICALS-RT study, although we had fewer patients with positive margins. Radiotherapy can be avoided in patients with T3b prostate cancer, even if margin is positive, until there is definitive evidence of PSA recurrence. In keeping with the conclusion of RADICALS-RT, salvage radiotherapy may be preferable to adjuvant radiotherapy.
Identifiants
pubmed: 36714225
doi: 10.1097/CU9.0000000000000115
pii: CURR-UROL_220013
pmc: PMC9875210
doi:
Types de publication
Journal Article
Langues
eng
Pagination
227-231Déclaration de conflit d'intérêts
No conflict of interest has been declared by the authors.
Références
Cancer. 2006 Jun 1;106(11):2369-75
pubmed: 16649221
J Clin Oncol. 2003 Nov 1;21(21):3972-8
pubmed: 14581419
Lancet. 2012 Dec 8;380(9858):2018-27
pubmed: 23084481
BJU Int. 2011 Feb;107(3):383-8
pubmed: 21265985
Int J Urol. 2019 Apr;26(4):458-464
pubmed: 30659663
Urol Oncol. 2014 Jan;32(1):26.e1-7
pubmed: 23395235
Eur Urol Focus. 2018 Apr;4(3):369-375
pubmed: 28753838
Int Urol Nephrol. 2007;39(4):1097-102
pubmed: 17431809
Lancet. 2009 Jan 24;373(9660):301-8
pubmed: 19091394
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
J Clin Oncol. 2014 Dec 10;32(35):3939-47
pubmed: 25245445
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Lancet Oncol. 2020 Oct;21(10):1331-1340
pubmed: 33002437
Adv Urol. 2012;2012:164263
pubmed: 22216025
Eur Urol. 2019 Nov;76(5):586-595
pubmed: 31375279
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Radiology. 2002 Jul;224(1):203-10
pubmed: 12091684
Eur Urol. 2016 Aug;70(2):233-45
pubmed: 26215604
Sci Rep. 2020 Mar 30;10(1):5693
pubmed: 32231265
J Urol. 2008 Dec;180(6):2453-7; discussion 2458
pubmed: 18930488
PLoS One. 2019 Jan 25;14(1):e0210514
pubmed: 30682036
Lancet. 2020 Oct 31;396(10260):1422-1431
pubmed: 33002431
BJU Int. 2011 May;107(9):1419-24
pubmed: 20804475
J Urol. 2011 May;185(5):1691-7
pubmed: 21419448
Lancet Oncol. 2020 Oct;21(10):1341-1352
pubmed: 33002438
Lancet. 2020 Oct 31;396(10260):1413-1421
pubmed: 33002429
Eur Urol Oncol. 2019 Feb;2(1):110-117
pubmed: 30929840
Eur Urol. 2014 Aug;66(2):243-50
pubmed: 24680359
Urology. 2004 Feb;63(2):333-6
pubmed: 14972484